Neurocrine BiosciencesNBIX
NBIX
About: Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Employees: 1,800
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
51% more first-time investments, than exits
New positions opened: 109 | Existing positions closed: 72
21% more capital invested
Capital invested by funds: $10.7B [Q3] → $12.9B (+$2.2B) [Q4]
20% more funds holding in top 10
Funds holding in top 10: 10 [Q3] → 12 (+2) [Q4]
4% more funds holding
Funds holding: 564 [Q3] → 587 (+23) [Q4]
1.44% more ownership
Funds ownership: 91.71% [Q3] → 93.15% (+1.44%) [Q4]
9% more call options, than puts
Call options by funds: $48M | Put options by funds: $44.2M
3% more repeat investments, than reductions
Existing positions increased: 212 | Existing positions reduced: 206
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$137
27%
upside
Avg. target
$159
47%
upside
High target
$185
72%
upside
11 analyst ratings
11 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Sumant Kulkarni 10% 1-year accuracy 3 / 30 met price target | 47%upside $158 | Buy Maintained | 28 Apr 2025 |
Evercore ISI Group Cory Kasimov 47% 1-year accuracy 8 / 17 met price target | 72%upside $185 | Outperform Maintained | 24 Apr 2025 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 354 met price target | 56%upside $168 | Buy Maintained | 22 Apr 2025 |
Needham Ami Fadia 22% 1-year accuracy 35 / 160 met price target | 28%upside $138 | Buy Upgraded | 15 Apr 2025 |
RBC Capital Brian Abrahams 19% 1-year accuracy 13 / 70 met price target | 27%upside $137 | Outperform Upgraded | 14 Apr 2025 |
Financial journalist opinion
Based on 6 articles about NBIX published over the past 30 days
Neutral
PRNewsWire
10 hours ago
Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia
SAN DIEGO , April 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568, the company's investigational oral muscarinic M4 selective orthosteric agonist, as a potential treatment for schizophrenia. Positive top-line data for the Phase 2 clinical study in adults with schizophrenia were reported in August 2024.
Neutral
PRNewsWire
6 days ago
Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry
Post-hoc analysis of higher risk older adults showed substantial and sustained improvements in tardive dyskinesia symptoms with no new treatment-emergent adverse events of clinical concern SAN DIEGO , April 24, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a post-hoc analysis from two 48-week studies, the KINECT® 3 extension and KINECT® 4, demonstrating the long-term safety profile and robust efficacy of INGREZZA® (valbenazine) capsules in adults aged 65 years and older with tardive dyskinesia (TD) in The Journal of Clinical Psychiatry. This represents the first and only published peer-reviewed analysis of a vesicular monoamine transporter 2 inhibitor for the treatment of TD in older adults (≥65 years), a group at higher risk for TD and associated consequences.
Positive
Seeking Alpha
1 week ago
Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025
Company's valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in 2025, targeting patients unresponsive to antipsychotics. The company also anticipates phase 3 data for valbenazine in treating dyskinetic cerebral palsy in 2025, presenting another market opportunity. Neurocrine's financial health is robust, with $1.8 billion in cash and strong revenue growth from INGREZZA, which saw a 23% year-over-year increase in Q4 2024.
Positive
Seeking Alpha
2 weeks ago
Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity
Neurocrine Biosciences, Inc. has shown significant growth since its 1996 IPO, with a current stock price around $100, reflecting an 850% increase. Ingrezza is the flagship, >$2bn p.a. selling product. Despite a recent sell-off due to missed earnings targets and cautious 2025 guidance, Neurocrine's pipeline, including the newly approved Crenessity, may offer substantial growth potential. The company's robust portfolio and promising pipeline, including potential blockbusters like Crenessity and Ingrezza (valbenazine) label expansions, make it an intriguing contrarian buy opportunity.
Neutral
PRNewsWire
3 weeks ago
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO , April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025.
Neutral
PRNewsWire
4 weeks ago
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
All Patients Treated with INGREZZA® (valbenazine) Capsules Reached a Therapeutic Dose from Day One, While Only Approximately Half of Patients Treated with Deutetrabenazine Were Able to Reach a Therapeutic Dose Within Six Months Findings Presented at the Academy of Managed Care Pharmacy 2025 Annual Meeting SAN DIEGO , March 31, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from a real-world study showing that all patients with tardive dyskinesia achieved a therapeutic dose with INGREZZA® (valbenazine) capsules upon initiation of treatment. This retrospective cohort study will be presented at the Academy of Managed Care Pharmacy 2025 Annual Meeting in Houston, Texas.
Positive
The Motley Fool
1 month ago
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential
Explore the exciting world of Neurocrine Biosciences (NBIX -1.47%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Neutral
PRNewsWire
1 month ago
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder Findings Presented at the 2025 Psychiatry Update Conference SAN DIEGO , March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily INGREZZA® (valbenazine) capsules. This analysis was presented at the 2025 Psychiatry Update Conference in Chicago.
Neutral
24/7 Wall Street
1 month ago
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
If you work in the biotech industry, you might know the name Alex Denner.
Neutral
PRNewsWire
1 month ago
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
Data Reinforce the Clinically Meaningful Impact of INGREZZA in Adults with Huntington's Disease Chorea Findings Presented at the 2025 American Association of Neuroscience Nurses Neuroscience Advanced Practice Provider Symposium SAN DIEGO , March 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the KINECT®-HD study showcasing significant improvements in chorea across body regions with once-daily INGREZZA® (valbenazine) capsules in adults with Huntington's disease. The post-hoc analysis was presented at the Neuroscience Advanced Practice Provider Symposium hosted by the American Association of Neuroscience Nurses in New Orleans.
Charts implemented using Lightweight Charts™